Avacta Group PLC - Yorkshire-based drug and diagnostic equipment developer - Submits declaration of conformity for rapid Covid-19 lateral flow test to the UK's Medicines & Healthcare Products Regulatory Agency. Expects registration of test to be confirmed in the coming days, before it is immediately placed on the market. The test has been shown to be more sensitive than lateral flow tests currently on the market, particularly for lower viral loads.
Current stock price: 266.88 pence, up 1.9% on Monday
Year-to-date change: more than doubled from 114.0p on December 31
By Ivan Edwards; ivanedwards@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Avacta Group (AVCT)